48 results on '"Wu, Y.-L."'
Search Results
2. 1279P First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study.
3. P4.17F.05 Adherence to Clinical Practice Guideline - Analysis of 89 Multidisciplinary Team Discussed Patients with Stage III Lung Cancer.
4. EP.17F.02 Three-Stage Evolution of Lung Cancer Multidisciplinary Team in China.
5. EP.15A.03 Lung Cancer Multidisciplinary Teams in China Show Multi-faceted Similarities and Differences Compared to Europe and Canada.
6. EP.12D.05 MAIC of OS and TRAE Comparing Capmatinib with Other MET Inhibitors for Treatment of Ansclc with MET Exon 14 Skipping Mutations.
7. EP.09B.03 Salvage Surgery Following Inductiontherapy for Advanced ALK-Positive NSCLC: Pathological Response and Surgical Outcomes.
8. EP.01D.02 Heterogeneous Germline Variants Detected in EGFR-Mutant Familial Lung Cancer Patients and Family Members.
9. P4.07E.07 Spatial Memory B Cells Activation by CXCL13+ Th Cells via the MIF(CD74-CXCR4) Axis may Improve Immunotherapy Efficacy in HER2 Mutant NSCLC.
10. P2.07C.03 Limited Efficacy of Immunochemotherapy in Pulmonary Invasive Mucinous Adenocarcinoma and Mucoepidermoid Carcinoma as Neoadjuvant Setting.
11. P1.06B.14 Optimal Cut-Off with NGS for Metamplification Andclinical Relevance to MET Inhibitor in Non-Small-Cell Lung Cancer.
12. P1.06A.04 Deep Learning-based Whole Slide Image Analysis Predicts PD-L1 Status from H&E-Stained Histopathology Images in Lung Cancer.
13. P1.03G.02 Genotyping of RB1 Status Identifies Two Distinct Subtypes in EGFR-Mutant Lung Cancers with SCLC Transformation.
14. MA15.11 Neoadjuvant Sintilimab plus Chemotherapy in EGFR-mutant NSCLC Followed by adjuvant Osimertinib or Observation: A Phase II CTONG2104 Trial.
15. OA06.03 SAFFRON-301: Tislelizumab Plus Sitravatinib in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1.
16. OA05.05 Pre-Local Consolidative Therapy Circulating Circulating Tumor DNA Defines Molecular Oligometastatic Non-Small Cell Lung Cancer.
17. PL04.04 Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC.
18. EP.06G.18 Lung Cancer with Pleural Dissemination is Potentially a Non-Shedding Tumor
19. P4.11E.12 First Line Camrelizumab for Brain Metastases of NSCLC (CTONG 2003): A Randomized Controlled Trial
20. P1.08B.01 Predicting Tumor Recurrence Risk in Locally Advanced NSCLC with Detectable ctDNA-Based Molecular Residual Disease: An Xgboost Model Analysis
21. MA15.05 Follow-Up Update of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer
22. MA12.10 Zongertinib (BI 1810631) For HER2-Positive Solid Tumors with Brain Metastases: Subanalysis of the Beamion LUNG-1 Trial
23. MA09.09 Genomic Mapping of Evolutionary from Pre-Invasive to Advanced Stage in Lung Adenocarcinoma
24. MA07.08 Proteogenomic Analysis of CSF Reveals Distinct Molecular Patterns of Leptomeningeal Metastases in EGFR-Mutated NSCLC
25. MA06.05 A Phase II Study of Lorlatinib in Advanced ROS1+ NSCLC Pre-Treated with Crizotinib and Platinum-Based Chemotherapy
26. MA06.07 Patterns of Progression with Lorlatinib and Insights into Subsequent Anticancer Therapy Efficacy in Advanced ALK+ NSCLC
27. OA14.05 KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study
28. OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)
29. LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
30. 1382P Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations
31. 1315P BC3195, a novel ADC targeting CDH3: Preliminary results of a first-in human phase I study in patients with advanced solid malignancies
32. 1272P Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
33. 1255MO A phase II safety and efficacy study of PM8002/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
34. 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)
35. 997MO A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01
36. 642P Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC
37. EP.17A.08 Development of the First Lung Cancer Clinical Pathway in Chinese Counties
38. P4.11E.16 Clinical Outcome of HER2-mut NSCLC Treated with First-Line Immunotherapy-Based Regimens versus Chemotherapy/HER2-TKIs
39. MA11.05 Nivolumab + Ipilimumab vs Chemotherapy in Patients with Stage IV/recurrent NSCLC and PD-L1 ≥ in China: Checkmate 227 CHESS
40. P3.12D.06 Beamion LUNG-1 And LUNG-2: The Zongertinib Clinical Program in Patients with Non-Small Cell Lung Cancer and HER2 Mutations
41. P3.08F.02 MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model (APPROACH)
42. A0889 - Reproductive outcomes in infertile couples undergoing intracytoplasmic sperm injection with a male partner exhibiting chromosomal translocation or inversion.
43. [Short-term effects of laparoscopic sleeve gastrectomy combined with reconstruction of the acute His angle on postoperative gastroesophageal reflux disease].
44. [ELOC-mutated renal cell carcinoma with new mutation site combined with lung adenocarcinoma: report of a case].
45. [Research on the status and development of medical and public health informatization in China, from the perspective of medical and preventive integration].
46. [Two cases of pyridaben poisoning were successfully treated by blood purification].
47. [Progress in research of rash and fever syndrome surveillance and early warning].
48. [Clinical pathway in Chinese county for lung cancer diagnosis and treatment (2023 edition)].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.